Our Company
Thetis is a clinical-stage pharmaceutical company developing TP-317, a first-in-class, oral BLT1 agonist, for inflammatory bowel disease.
TP-317
TP-317 is an oral, stabilized form of Resolvin E1 (RvE1) that activates BLT1 on epithelial and immune cells to promote repair and resolution.
Clinical Progress
A 12-week Phase 1b study (NCT07834515) in moderate-to-severe ulcerative colitis is recruiting in Eastern Europe.
September 30, 2026
September 17, 2026